CytomX Therapeutics, Inc. (CTMX) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone. Thank you for standing by. Welcome to the Cytomics Therapeutics 2025 Financial Results and Faceta Phase 1 Dose Expansion Data Call. Please be advised that today's conference is being recorded. I would now like to hand the conference call over to your host for today, Chris Ogden, Cytomics Chief Financial Officer. Please go ahead. Thank you. Good morning, and thank you for joining us. Before we begin, I would like to remind everyone that during this call, we'll be making forward-looking statements. Because forward-looking statements relate to the future, they're subject to inherent uncertainties and risks that are difficult to predict, and many of which are outside of our control. Important risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov. We undertake no obligation to update any forward-looking statements, whether as a result of new information future developments, or otherwise. Earlier today, we issued a press release that includes a summary of our 2025 financial results and progress at Cytomix. Additionally, this morning, we are excited to announce positive phase one dose expansion data for Varsetta N in patients with late-line colorectal cancer. The focus of our call today will be the phase one expansion data update for Varsetta. For details on the company's 2025 financial results and other pipeline updates, we encourage everyone to read today's press releases and the associated materials which have been filed with the SEC. Additionally, the press releases, a recording of this call, and our SEC filings can be found under the investors and news section of our website. With me on the call today are Dr. Shawn McCarthy, Cytomix's Chief Executive Officer and Chairman, and Dr. Wayne Chiu, Cytomix's Ch...